TectorigeninCAS# 548-77-6 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 548-77-6 | SDF | Download SDF |
PubChem ID | 5281811 | Appearance | Light yellow powder |
Formula | C16H12O6 | M.Wt | 300.26 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Synonyms | Tectrigenin; 4',5,7-Trihydroxy 6-methoxyisoflavone | ||
Solubility | DMSO : 150 mg/mL (499.57 mM; Need ultrasonic and warming) | ||
Chemical Name | 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one | ||
SMILES | COC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)O | ||
Standard InChIKey | OBBCRPUNCUPUOS-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H12O6/c1-21-16-11(18)6-12-13(15(16)20)14(19)10(7-22-12)8-2-4-9(17)5-3-8/h2-7,17-18,20H,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Tectorigenin has hepatoprotective, antifibrotic, anti-leukemia, antioxidant, and anti-inflammatory activities, it could sensitize paclitaxel-resistant human ovarian cancer cells through inactivation of the Akt/IKK/IκB/NFκB signaling pathway, and promise a new intervention to chemosensitize paclitaxel-induced cytotoxicity in ovarian cancer. |
Targets | PPAR | NF-kB | IkB | TNF-α | p65 | IL Receptor | NOS | COX | NO | PGE | Caspase | Akt | IKK |
In vitro | Tectorigenin regulates adipogenic differentiation and adipocytokines secretion via PPARγ and IKK/NF-κB signaling.[Pubmed: 25856699]Pharm Biol. 2015 Apr 9:1-9.Obesity is associated with a number of diseases with metabolic abnormalities such as type 2 diabetes (T2D). OBJECTIVE: We investigate the effects of Tectorigenin on 3T3-L1 preadipocyte differentiation and adipocytokines secretion. Tectorigenin inhibits IFN-γ/LPS-induced inflammatory responses in murine macrophage RAW 264.7 cells.[Reference: WebLink]Arch. Pharm. Res., 2008, 31(11):1447-56.Tectorigenin (Tg) and tectoridin (Td) are the major compounds isolated from the rhizomes of iridaceous plant Belamcanda chinensis which is well known as a chinese traditional medicine for the treatment of inflammatory diseases.
|
In vivo | Tectorigenin inhibits the inflammation of LPS-induced acute lung injury in mice.[Pubmed: 25480515]Chin J Nat Med. 2014 Nov;12(11):841-6.In a previous study, the anti-inflammatory effects of Tectorigenin were disclosed. In this study, the anti-inflammatory effects of Tectorigenin on acute lung injury using a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model were investigated. Tectorigenin inhibits the in vitro proliferation and enhances miR-338* expression of pulmonary fibroblasts in rats with idiopathic pulmonary fibrosis.[Pubmed: 20600766 ]J Ethnopharmacol. 2010 Aug 19;131(1):165-73.Tectorigenin is one of the main components in rhizomes of Iris tectorum, which is traditionally used to treat disorders such as hepatic cirrhosis caused by fibrosis. Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is caused by accumulation of fibroblasts in lungs.
In this work we sought to examine the effects of Tectorigenin on pulmonary fibroblasts in the IPF animal model and investigated the molecular mechanism (microRNA regulation) of Tectorigenin treatment.
|
Cell Research | Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.[Pubmed: 23027625 ]Tectorigenin ablates the inflammation-induced epithelial-mesenchymal transition in a co-culture model of human lung carcinoma.[Pubmed: 25712668]Pharmacol Rep. 2015 Apr;67(2):382-7.Tumors not only manage to escape from the host immune system, but they effectively contrive to benefit from infiltrating immune cells by modifying their functions so as to create a pro-inflammatory microenvironment favorable for tumor progression and metastasis. In this study we investigated if Tectorigenin could suppress lung cancer-induced pro-inflammatory response generated from monocytes. Carcinogenesis. 2012 Dec;33(12):2488-98.Paclitaxel (Taxol) is currently used as the front-line chemotherapeutic agent for several cancers including ovarian carcinoma; however, the drug frequently induces drug resistance through multiple mechanisms. The new strategy of using natural compounds in combination therapies is highly attractive because those compounds may enhance the efficacy of chemotherapy.
|
Animal Research | Hepatoprotective effect of tectoridin and tectorigenin on tert-butyl hyperoxide-induced liver injury.[Pubmed: 15821336]J Pharmacol Sci. 2005 Apr;97(4):541-4.To clarify the hepatoprotective effects of tectoridin and Tectorigenin from Puerariae Flos, their effects on tert-butyl hyperoxide (t-BHP)-injured HepG2 cells and mice were investigated.
|
Tectorigenin Dilution Calculator
Tectorigenin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3304 mL | 16.6522 mL | 33.3045 mL | 66.6089 mL | 83.2612 mL |
5 mM | 0.6661 mL | 3.3304 mL | 6.6609 mL | 13.3218 mL | 16.6522 mL |
10 mM | 0.333 mL | 1.6652 mL | 3.3304 mL | 6.6609 mL | 8.3261 mL |
50 mM | 0.0666 mL | 0.333 mL | 0.6661 mL | 1.3322 mL | 1.6652 mL |
100 mM | 0.0333 mL | 0.1665 mL | 0.333 mL | 0.6661 mL | 0.8326 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Irigenin
Catalog No.:BCN3849
CAS No.:548-76-5
- Quercetagetin-7-O-glucoside
Catalog No.:BCN6480
CAS No.:548-75-4
- Crystal Violet
Catalog No.:BCC4772
CAS No.:548-62-9
- Cornin
Catalog No.:BCN5008
CAS No.:548-37-8
- Oxysanguinarine
Catalog No.:BCN8100
CAS No.:548-30-1
- Isolariciresinol
Catalog No.:BCN5727
CAS No.:548-29-8
- Isoginkgetin
Catalog No.:BCN2320
CAS No.:548-19-6
- Roemerine
Catalog No.:BCN8236
CAS No.:548-08-3
- Hypericin
Catalog No.:BCN5977
CAS No.:548-04-9
- BMS-345541
Catalog No.:BCC1423
CAS No.:547757-23-3
- JTE 013
Catalog No.:BCC7348
CAS No.:547756-93-4
- Fluvoxamine
Catalog No.:BCC4214
CAS No.:54739-18-3
- Pinobanksin
Catalog No.:BCN5729
CAS No.:548-82-3
- Galangin
Catalog No.:BCN5730
CAS No.:548-83-4
- Gyrophoric acid
Catalog No.:BCN5731
CAS No.:548-89-0
- Trichodesmine
Catalog No.:BCN2145
CAS No.:548-90-3
- Protoveratrine B
Catalog No.:BCN2435
CAS No.:124-97-0
- Daphneolone
Catalog No.:BCN3230
CAS No.:54835-64-2
- Roseoside
Catalog No.:BCN5728
CAS No.:54835-70-0
- Protogracillin(P)
Catalog No.:BCC8352
CAS No.:54848-30-5
- Sanshodiol
Catalog No.:BCN6577
CAS No.:54854-91-0
- PD 334581
Catalog No.:BCC6300
CAS No.:548756-68-9
- Arborinine
Catalog No.:BCN7438
CAS No.:5489-57-6
- Amitriptyline HCl
Catalog No.:BCC5033
CAS No.:549-18-8
Tectorigenin inhibits the in vitro proliferation and enhances miR-338* expression of pulmonary fibroblasts in rats with idiopathic pulmonary fibrosis.[Pubmed:20600766]
J Ethnopharmacol. 2010 Aug 19;131(1):165-73.
UNLABELLED: Tectorigenin is one of the main components in rhizomes of Iris tectorum, which is traditionally used to treat disorders such as hepatic cirrhosis caused by fibrosis. Idiopathic pulmonary fibrosis (IPF), one of the most common interstitial lung diseases, is caused by accumulation of fibroblasts in lungs. AIM OF THE STUDY: In this work we sought to examine the effects of Tectorigenin on pulmonary fibroblasts in the IPF animal model and investigated the molecular mechanism (microRNA regulation) of Tectorigenin treatment. MATERIALS AND METHODS: A well-known animal disease model of pulmonary fibrosis in rat was established by intratracheally instilling of bleomycin. In vitro cultured pulmonary fibroblasts in bleomycin-treated rats and in controls were treated with or without Tectorigenin. Comparative analyses of cell proliferation, apoptosis and cell cycle of pulmonary fibroblasts in bleomycin-treated rats and in controls were performed. Expression of miR-338* and its candidate gene LPA1 related to IPF of Tectorigenin-treated pulmonary fibroblasts in bleomycin-treated rats were further investigated. RESULTS: Tectorigenin significantly inhibited the proliferation of pulmonary fibroblasts in bleomycin-treated rats but not in controls. However, no altered cell cycle and apoptosis of pulmonary fibroblasts in bleomycin-treated rats and in controls was observed after Tectorigenin treatment. Tectorigenin remarkably enhanced miR-338* expression of pulmonary fibroblasts in bleomycin-treated rats and downregulated LPA1 in the protein level. CONCLUSIONS: Tectorigenin inhibits the proliferation of pulmonary fibroblasts in vitro and enhances miR-338* expression, which might in turn downregulate LPA1. This indicates a potential inhibitory role of Tectorigenin on the pathogenesis of IPF.
Hepatoprotective effect of tectoridin and tectorigenin on tert-butyl hyperoxide-induced liver injury.[Pubmed:15821336]
J Pharmacol Sci. 2005 Apr;97(4):541-4. Epub 2005 Apr 9.
To clarify the hepatoprotective effects of tectoridin and Tectorigenin from Puerariae Flos, their effects on tert-butyl hyperoxide (t-BHP)-injured HepG2 cells and mice were investigated. When Tectorigenin at a dose of 50 mg/kg was intraperitoneally administered to mice injured by t-BHP, it significantly inhibited the increase the activities of plasma ALT and AST by 39% and 41%, respectively, in the t-BHP-treated group. The inhibitory effect of Tectorigenin is much more potent than that of a commercially available dimethyl diphenyl bicarboxylate. Orally administered tectoridin showed hepatoprotective activity. However, when tectoridin was intraperitoneally administrated to mice, no hepatoprotective activity was observed. Tectorigenin also protected against the cytotoxicity of HepG2 cells induced by t-BHP. This protection may have originated from the inhibition of apoptosis. Tectorigenin may be hepatoprotective and tectoridin should be a prodrug that is transformed to Tectorigenin.
Tectorigenin regulates adipogenic differentiation and adipocytokines secretion via PPARgamma and IKK/NF-kappaB signaling.[Pubmed:25856699]
Pharm Biol. 2015;53(11):1567-75.
CONTEXT: Obesity is associated with a number of diseases with metabolic abnormalities such as type 2 diabetes (T2D). OBJECTIVE: We investigate the effects of Tectorigenin on 3T3-L1 preadipocyte differentiation and adipocytokines secretion. MATERIALS AND METHODS: The effects of Tectorigenin on adipocyte differentiation were studied using Oil Red O staining. Effects of Tectorigenin on adipogenesis-related genes expression and adipocytokines secretion were measured by the real-time quantitative RT-PCR and ELISA method, respectively. Reporter gene assays were performed to determine the PPARgamma and NF-kappaB transactivation. We also used [(3)H]-2-deoxy-d-glucose to study the glucose uptake, and the IKK/NF-kappaB signaling pathway was assessed by western blot analysis. HFD/STZ rats were used to evaluate the therapeutic efficacies of Tectorigenin. RESULTS: Tectorigenin 10, 25, 50, and 75 muM inhibited 3T3-L1 adipogenesis and related genes transcription. TNF-alpha-induced changes of IL-6, MCP-1, as well as adiponectin in 3T3-L1 were markedly reversed by Tectorigenin at 75 muM. Further investigation using reporter gene revealed that Tectorigenin was a partial PPARgamma agonist with an IC50 value of 13.3 muM. Tectorigenin improved basal and insulin-stimulated glucose uptake in mature 3T3-L1 adipocytes. Moreover, Tectorigenin antagonized TNF-alpha-induced NF-kappaB transactivation and p65 nuclear translocation. Although Tectorigenin (50 and 100 mg/kg) displayed the ability to promote insulin sensitivity and improve glucose metabolism in HFD/STZ rats, it did not cause significant side effects such as body weight gain, fluid retention, or cardiac hypertrophy. DISCUSSION AND CONCLUSION: These results suggest that Tectorigenin may ameliorate hyperglycemia by blocking preadipocyte differentiation and adipocytokines secretion in which PPARgamma and NF-kappaB signaling pathways were involved.
Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFkappaB pathway.[Pubmed:23027625]
Carcinogenesis. 2012 Dec;33(12):2488-98.
Paclitaxel (Taxol) is currently used as the front-line chemotherapeutic agent for several cancers including ovarian carcinoma; however, the drug frequently induces drug resistance through multiple mechanisms. The new strategy of using natural compounds in combination therapies is highly attractive because those compounds may enhance the efficacy of chemotherapy. In this study, we found that Tectorigenin, an isoflavonoid isolated from flower of Pueraria thunbergiana, enhanced the growth-inhibitory effect of paclitaxel in paclitaxel-resistant ovarian cancer cells (MPSC1(TR), A2780(TR) and SKOV3(TR)) as well as their naive counterparts. The combination of Tectorigenin with paclitaxel resulted in a synergistic apoptosis compared with either agent alone through activation of caspases-3, -8 and -9. Treatment with Tectorigenin inhibited the nuclear translocation of NFkappaB and the expression of NFkappaB-dependent genes such as FLIP, XIAP, Bcl-2, Bcl-xL and COX-2, which are known to be associated with chemoresistance. In addition, the Tectorigenin-paclitaxel combination inhibited the phosphorylation of IkappaB and IKK and the activation of Akt in paclitaxel-resistant cancer cells. Moreover, Tectorigenin-paclitaxel-induced cell growth inhibition was enhanced by pretreatment with the Akt inhibitor LY294002 or overexpression of the dominant negative Akt (Akt-DN), but reduced by overexpression of constitutively activated Akt (Akt-Myr). Furthermore, we found that Akt-Myr, at least in part, reversed Tectorigenin-paclitaxel-induced nuclear translocation of NFkappaB and the phosphorylation of IkappaB and IKK. These data suggest that Tectorigenin could sensitize paclitaxel-resistant human ovarian cancer cells through inactivation of the Akt/IKK/IkappaB/NFkappaB signaling pathway, and promise a new intervention to chemosensitize paclitaxel-induced cytotoxicity in ovarian cancer.
Tectorigenin ablates the inflammation-induced epithelial-mesenchymal transition in a co-culture model of human lung carcinoma.[Pubmed:25712668]
Pharmacol Rep. 2015 Apr;67(2):382-7.
OBJECTIVES: Tumors not only manage to escape from the host immune system, but they effectively contrive to benefit from infiltrating immune cells by modifying their functions so as to create a pro-inflammatory microenvironment favorable for tumor progression and metastasis. In this study we investigated if Tectorigenin could suppress lung cancer-induced pro-inflammatory response generated from monocytes. MATERIALS AND METHODS: A549:THP1 co-culture model was set-up favoring release of pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor alpha (TNF-alpha). Effect of Tectorigenin on A549 imparted invasive phenotype of A549:THP-1 co-culture was monitored by cytokine release from monocytes, and metastasis/epithelial-mesenchymal transitiom (EMT) in A549 cells. RESULTS: In a contact A549:THP1 co-culture model, THP-1 cells were activated by A549 cells favoring secretion of pro-inflammatory cytokines, TNF-alpha and IL-6. However, priming of A549 cells with Tectorigenin for 24h repressed A549 cell-induced secretion of TNF-alpha and IL-6 by THP-1 cells. Tectorigenin induced change in functional phenotype of A549 cells rendered THP-1 cells non-responsive for the secretion of IL-6 and TNF-alpha in a contact co-culture setup. Additionally, conditioned media from this non-responsive A549:THP-1 co-culture suppressed metastatic potential of A549 cells as confirmed by the wound healing and transwell migration assays. These finding were further corroborated by decrease in expression of Snail with a concomitant increase in E-cadherin, the two signature markers of EMT. CONCLUSION: These results clearly demonstrate the therapeutic potential of Tectorigenin to prevent lung cancer elicited inflammatory and pro-metastatic response in monocytes and warrants further investigations to elucidate its mechanism of action.
Tectorigenin inhibits the inflammation of LPS-induced acute lung injury in mice.[Pubmed:25480515]
Chin J Nat Med. 2014 Nov;12(11):841-6.
AIM: In a previous study, the anti-inflammatory effects of Tectorigenin were disclosed. In this study, the anti-inflammatory effects of Tectorigenin on acute lung injury using a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model were investigated METHOD: The cell-count in the bronchoalveolar lavage fluid (BALF) was measured. The animal lung edema degree was evaluated by the wet/dry weight (W/D) ratio. The superoxidase dismutase (SOD) activity and myeloperoxidase (MPO) activity was assayed using SOD and MPO kits, respectively. The levels of inflammatory mediators, including tumor necrosis factor-alpha (TNF-alpha), IL-1beta, and IL-6 were assayed using an enzyme-linked immunosorbent assay method. Pathological changes of lung tissues were observed through HE staining. The inflammatory signal pathway related protein nuclear factor NF-kappaB p65 mRNA expression was measured by real-time PCR, and the protein level of NF-kappaB p65 was measured using Western blotting analysis. RESULTS: The data showed that treatment with the Tectorigenin markedly attenuated the inflammatory cell numbers in the BALF, decreased nuclear factor NF-kappaB p65 mRNA level and protein level in the lungs, and improved SOD activity and inhibited MPO activity. Histological studies showed that Tectorigenin substantially inhibited LPS-induced neutrophils in lung tissue compared with the model group. CONCLUSION: The results indicated that Tectorigenin had a protective effect on LPS-induced ALI in mice.